JPH069421A - Oily preparation and method for producing the same - Google Patents
Oily preparation and method for producing the sameInfo
- Publication number
- JPH069421A JPH069421A JP4162666A JP16266692A JPH069421A JP H069421 A JPH069421 A JP H069421A JP 4162666 A JP4162666 A JP 4162666A JP 16266692 A JP16266692 A JP 16266692A JP H069421 A JPH069421 A JP H069421A
- Authority
- JP
- Japan
- Prior art keywords
- oil
- active oxygen
- raw material
- roasted
- sesame
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
- A23D9/02—Other edible oils or fats, e.g. shortenings or cooking oils characterised by the production or working-up
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B32—LAYERED PRODUCTS
- B32B—LAYERED PRODUCTS, i.e. PRODUCTS BUILT-UP OF STRATA OF FLAT OR NON-FLAT, e.g. CELLULAR OR HONEYCOMB, FORM
- B32B3/00—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form
- B32B3/10—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material
- B32B3/12—Layered products comprising a layer with external or internal discontinuities or unevennesses, or a layer of non-planar shape; Layered products comprising a layer having particular features of form characterised by a discontinuous layer, i.e. formed of separate pieces of material characterised by a layer of regularly- arranged cells, e.g. a honeycomb structure
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23D—EDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
- A23D9/00—Other edible oils or fats, e.g. shortenings or cooking oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L27/00—Spices; Flavouring agents or condiments; Artificial sweetening agents; Table salts; Dietetic salt substitutes; Preparation or treatment thereof
- A23L27/50—Soya sauce
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/115—Fatty acids or derivatives thereof; Fats or oils
- A23L33/12—Fatty acids or derivatives thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/104—Fermentation of farinaceous cereal or cereal material; Addition of enzymes or microorganisms
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L7/00—Cereal-derived products; Malt products; Preparation or treatment thereof
- A23L7/10—Cereal-derived products
- A23L7/152—Cereal germ products
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9794—Liliopsida [monocotyledons]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B29—WORKING OF PLASTICS; WORKING OF SUBSTANCES IN A PLASTIC STATE IN GENERAL
- B29D—PRODUCING PARTICULAR ARTICLES FROM PLASTICS OR FROM SUBSTANCES IN A PLASTIC STATE
- B29D24/00—Producing articles with hollow walls
- B29D24/002—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled
- B29D24/005—Producing articles with hollow walls formed with structures, e.g. cores placed between two plates or sheets, e.g. partially filled the structure having joined ribs, e.g. honeycomb
-
- C—CHEMISTRY; METALLURGY
- C11—ANIMAL OR VEGETABLE OILS, FATS, FATTY SUBSTANCES OR WAXES; FATTY ACIDS THEREFROM; DETERGENTS; CANDLES
- C11B—PRODUCING, e.g. BY PRESSING RAW MATERIALS OR BY EXTRACTION FROM WASTE MATERIALS, REFINING OR PRESERVING FATS, FATTY SUBSTANCES, e.g. LANOLIN, FATTY OILS OR WAXES; ESSENTIAL OILS; PERFUMES
- C11B1/00—Production of fats or fatty oils from raw materials
- C11B1/06—Production of fats or fatty oils from raw materials by pressing
- C11B1/08—Production of fats or fatty oils from raw materials by pressing by hot pressing
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/52—Stabilizers
- A61K2800/522—Antioxidants; Radical scavengers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Botany (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Alternative & Traditional Medicine (AREA)
- Nutrition Science (AREA)
- Birds (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Medical Informatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
- Mechanical Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicinal Preparation (AREA)
- Cosmetics (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Anti-Oxidant Or Stabilizer Compositions (AREA)
Abstract
(57)【要約】
【目的】 有効成分である活性酸素抑制物質の活性が高
く、しかも疾患箇所である細胞内への浸透力が高い油性
製剤およびその製造方法を提供する。
【構成】 米または小麦の胚芽と大豆とからなる穀物原
料を100℃を超えない温度で焙煎し、次いで麹を加え
て醗酵させた後に微粉末化したものを、前記の方法で焙
煎したゴマから採取した油と生ゴマから採取した油とか
らなる混合油に添加してなり、前記微粉末と前記混合油
の合計量に対する前記混合油の割合を60〜95重量%
にした油性製剤である。この油性製剤は、ヒトの体内で
産生される活性酸素や過酸化脂質による細胞組織の破壊
に起因して発症する各種炎症、難病の予防、治療に適用
される。(57) [Summary] [Object] To provide an oil-based preparation having a high activity of an active oxygen-inhibiting substance as an active ingredient and a high penetration into cells at a disease site, and a method for producing the same. [Structure] A grain raw material composed of rice or wheat germ and soybeans is roasted at a temperature not exceeding 100 ° C., then koji is added and fermented, and then finely pulverized, which is roasted by the above method. It is added to a mixed oil consisting of oil collected from sesame and oil collected from raw sesame, and the ratio of the mixed oil to the total amount of the fine powder and the mixed oil is 60 to 95% by weight.
It is an oil-based formulation. This oily preparation is applied to the prevention and treatment of various inflammations and incurable diseases caused by destruction of cell tissues by active oxygen and lipid peroxides produced in the human body.
Description
【0001】[0001]
【産業上の利用分野】本発明は、油性製剤およびその製
造方法に関し、特に、ヒトの体内の活性酸素や過酸化脂
質の産生を抑制する物質(以下、活性酸素抑制物質とい
う)を有効成分として含有する油性製剤に関するもので
ある。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to an oily preparation and a method for producing the same, and in particular, a substance that suppresses the production of active oxygen and lipid peroxide in human body (hereinafter referred to as active oxygen inhibitor) as an active ingredient. The present invention relates to an oily preparation to be contained.
【0002】[0002]
【従来の技術】近年、ヒトの体内で産生される活性酸素
や過酸化脂質による細胞組織の破壊に起因して発症する
各種炎症、難病(慢性関節リウマチ、血栓性静脈炎、進
行性全身性皮膚硬化症、バージャー氏病、レイノー氏
病、難治性皮膚潰瘍など)の予防、治療に用いて優れた
効果を発揮する活性酸素抑制物が注目されている。2. Description of the Related Art In recent years, various inflammations and incurable diseases (rheumatoid arthritis, thrombophlebitis, progressive systemic skin) caused by destruction of cell tissues by active oxygen and lipid peroxides produced in the human body. Attention has been focused on active oxygen-suppressing substances that exert excellent effects when used for the prevention and treatment of sclerosis, Burger's disease, Raynaud's disease, and intractable skin ulcers.
【0003】上記活性酸素抑制物質は、植物体に含まれ
るフラボノイド類、ポリフェノール類、タンニン、トコ
フェロール、ビタミンB1 などの低分子物質からなり、
これを医薬あるいは健康食品として経口摂取することに
より、上記した活性酸素や過酸化脂質の体内産生を抑制
することが本発明者らの研究によって明らかにされてい
る(昭和62年12月1日発行、日本薬剤師会雑誌第3
9巻第12号別冊「SOD(Superoxide dismutase)と生
薬のBioavailability」P1097〜P
1119参照)。The above-mentioned active oxygen suppressing substances are low molecular substances such as flavonoids, polyphenols, tannins, tocopherols and vitamin B 1 contained in plants.
It has been clarified by the study of the present inventors that the oral production of this as a medicine or a health food suppresses the above-mentioned production of active oxygen and lipid peroxide in the body (published on December 1, 1987). , Japan Association of Pharmacists No. 3
Vol. 9 No. 12 Separate Volume "SOD (Superoxide dismutase) and Bioavailability of Crude Drugs" P1097 to P
1119).
【0004】従来、この種の活性酸素抑制物質を含有す
る製剤として、特許第1366268号の植物系栄養剤
や、本発明者らによって開発された特開昭63−798
34号公報記載の活性酸素抑制組成物などが知られてい
る。Conventionally, as a preparation containing an active oxygen suppressing substance of this kind, a plant-based nutrient as disclosed in Japanese Patent No. 1366268 and JP-A-63-798 developed by the present inventors.
The active oxygen suppressing composition described in JP-A No. 34-34 is known.
【0005】前者の植物系栄養剤は、焼炒粉砕した玄米
粉および大豆粉に緑茶粉を混合し、これにコウジ(麹)
菌を少量添加して粉末としたものをゴマ油および大豆油
よりなる植物性混合油中に4日前後浸漬して有効成分を
抽出した後、遠心分離で沈殿物を除き、残った油状物を
ゼラチンなどのカプセルに封入したものである。The former plant nutrient is a mixture of brown rice powder and soybean powder that have been roasted and crushed with green tea powder, and this is then mixed with koji.
The powder was prepared by adding a small amount of bacteria and soaked in a vegetable oil mixture consisting of sesame oil and soybean oil for about 4 days to extract the active ingredient, and then the precipitate was removed by centrifugation to remove the remaining oily substance from gelatin. It is enclosed in a capsule such as.
【0006】後者の活性酸素抑制組成物は、植物種子ま
たはその胚芽を焙煎し、次いで微生物を加えて醗酵せし
め、これに焙煎した植物より得た植物油を添加してなる
ものであって、必要に応じてさらにビタミンC、ビタミ
ンC誘導体またはこれらを含有する植物体が添加され
る。The latter active oxygen-inhibiting composition is obtained by roasting plant seeds or their germs, then adding microorganisms and fermenting them, and adding vegetable oil obtained from the roasted plants to them. Vitamin C, a vitamin C derivative, or a plant body containing them is further added, if necessary.
【0007】上記植物種子としては、前記フラボノイド
類、ポリフェノール類、タンニン、トコフェロール、ビ
タミンB1 などの活性酸素抑制物質を豊富に含有する
米、小麦、大麦、大豆、小豆、とうもろこし、はとむ
ぎ、えんどうなどの種子が使用され、植物油としては、
ゴマ油、大豆油、綿実油、とうもろこし油、サフラワー
油、月見草油、糠油、菜種油、オリーブ油などが使用さ
れる。Examples of the plant seeds include rice, wheat, barley, soybeans, red beans, corn, corn, pea and pea, which are rich in active oxygen suppressing substances such as flavonoids, polyphenols, tannins, tocopherols and vitamin B 1. Seeds such as are used as vegetable oil,
Sesame oil, soybean oil, cottonseed oil, corn oil, safflower oil, evening primrose oil, bran oil, rapeseed oil, olive oil and the like are used.
【0008】[0008]
【発明が解決しようとする課題】しかしながら、前記植
物系栄養剤は、その原料となる植物体の加工方法などに
問題があるため、有効成分である活性酸素抑制物質の活
性が低いという欠点があった。However, the above-mentioned plant-based nutrient has a problem that the active oxygen-suppressing substance, which is an active ingredient, has a low activity because it has a problem in a method of processing a plant body as a raw material. It was
【0009】本発明者らの開発になる前記活性酸素抑制
組成物は、かかる欠点の改善を目的としてなされたもの
であって、原料となる植物体を遠赤外線でゆっくり焙煎
して活性酸素抑制物質の高温による失活を防ぐと共に、
有効成分の遊離低分子化を図り、さらに焙煎後の原料を
醗酵させて有効成分の遊離低分子化を促進することによ
り、活性酸素抑制物質の活性を著しく向上させることに
成功している。The active oxygen-suppressing composition developed by the present inventors has been made for the purpose of improving such drawbacks, and a raw material plant is slowly roasted by far infrared rays to suppress active oxygen. Prevents deactivation due to high temperature of the substance,
By reducing the free molecular weight of the active ingredient and further fermenting the raw material after roasting to promote the free low molecular weight of the active ingredient, the activity of the active oxygen inhibitor has been remarkably improved.
【0010】ところが、本発明者らのその後の研究によ
り、上記活性酸素抑制組成物は、試験管内では活性酸素
や過酸化脂質の産生を著しく抑制するにもかかわらず、
ヒトの体内ではこの抑制作用が必ずしも有効に発揮さな
いことが明らかになった。However, according to the subsequent research conducted by the present inventors, the above active oxygen-suppressing composition remarkably suppressed the production of active oxygen and lipid peroxide in a test tube.
It was revealed that this inhibitory effect is not always effectively exerted in the human body.
【0011】本発明者らは、その原因を次のように考え
ている。すなわち、活性酸素や過酸化脂質によって炎症
反応などの疾患が生じている細胞内に活性酸素抑制物質
が到達するためには、細胞の表面を覆っている細胞膜を
通過しなければならない。ところが、ヒトの細胞膜は油
脂分に富み、従って油性物質しか通過させないという性
質があるため、油性物質の含有量が低い上記活性酸素抑
制組成物は、細胞膜を通過して細胞内に浸透する能力が
低い。The present inventors consider the cause as follows. That is, in order for an active oxygen inhibitor to reach a cell in which a disease such as an inflammatory reaction is caused by active oxygen or lipid peroxide, it must pass through the cell membrane covering the surface of the cell. However, since human cell membranes are rich in fats and oils, and therefore have the property of allowing only oily substances to pass, the above active oxygen-suppressing composition having a low oily substance content has the ability to penetrate cells through cell membranes. Low.
【0012】そこで本発明者らは、上記活性酸素抑制組
成物の細胞膜通過能を改善すべく研究を重ねると共に、
原料となる植物種の選定やその加工方法などにも一層の
改善を加えた結果、有効成分である活性酸素抑制物質の
活性が高く、しかも疾患が生じている細胞内への浸透力
が高い油性製剤を見出すことにより、本発明に到達した
ものである。[0012] Therefore, the inventors of the present invention have conducted repeated studies to improve the ability of the above active oxygen-suppressing composition to cross cell membranes,
As a result of further improvements in the selection of plant species used as raw materials and their processing methods, the active oxygen inhibitor, which is the active ingredient, has a high activity, and the ability to penetrate into cells with disease is high. The invention has been reached by finding a formulation.
【0013】すなわち、本発明の目的は、有効成分であ
る活性酸素抑制物質の活性が高く、しかも疾患箇所であ
る細胞内への浸透力が高い油性製剤およびその製造方法
を提供することにある。That is, an object of the present invention is to provide an oily preparation having a high activity of an active oxygen suppressing substance which is an active ingredient and a high penetrating power into cells at a disease site, and a method for producing the same.
【0014】[0014]
【課題を解決するための手段】本発明の油性製剤は、米
胚芽または小麦胚芽と大豆とからなる穀物原料を100
℃を超えない温度で焙煎し、次いで麹を加えて醗酵させ
た後に微粉末化したものを、前記と同様の方法で焙煎し
たゴマから採取した油と生ゴマから採取した油とからな
る混合油に添加したものであって、前記微粉末と前記混
合油の合計量に対する前記混合油の割合は、60〜95
重量%である。The oil-based preparation of the present invention comprises 100 grains of raw material of rice germ or wheat germ and soybean.
Roasted at a temperature not exceeding ℃, then fermented by adding malt and then pulverized into oil, which consists of oil extracted from sesame roasted in the same manner as above and oil extracted from raw sesame It is added to the mixed oil, and the ratio of the mixed oil to the total amount of the fine powder and the mixed oil is 60 to 95.
% By weight.
【0015】活性酸素抑制物質を豊富に含有する原料と
しては、上記米胚芽、小麦胚芽および大豆の他、前記特
開昭63−79834号公報に記載された植物種(大
麦、小豆、とうもろこし、はとむぎ、えんどうなど)な
どがあるが、本発明者らの研究によると、米胚芽、小麦
胚芽および大豆が最も好適な原料である。As a raw material rich in active oxygen suppressing substances, in addition to the above-mentioned rice germ, wheat germ and soybean, the plant species (barley, red bean, corn, corn) described in the above-mentioned JP-A-63-79834. However, rice germ, wheat germ and soybean are the most suitable raw materials according to the studies by the present inventors.
【0016】上記米胚芽、小麦胚芽および大豆に次いで
好適な穀物原料は、糠、はとむぎおよび小麦である。従
って、米胚芽または小麦胚芽(両者を併用してもよい)
および大豆と共にこれら糠、はとむぎまたは小麦の少な
くとも一つを含んだ穀物原料を用いてもよい。また、い
ずれの場合も、穀物原料中に占める胚芽(米胚芽または
小麦胚芽)の割合は、少なくとも1重量%以上あること
が好ましい。Next to the rice germ, wheat germ and soybean, the preferred grain raw materials are bran, hatomugi and wheat. Therefore, rice germ or wheat germ (both may be used in combination)
Also, a grain raw material containing at least one of these bran, potato and wheat together with soybean may be used. In any case, the proportion of the germ (rice germ or wheat germ) in the grain raw material is preferably at least 1% by weight or more.
【0017】上記穀物原料中の活性酸素抑制物質は、他
の物質と共に複雑な高分子重合体を形成しており、その
ままでは活性がないので、焙煎などの手段によって高分
子結合を切断し、低分子化してやる必要がある。しか
し、焙煎温度が高すぎると、低分子化した活性酸素抑制
物質が失活してしまうため、この点にも配慮した焙煎条
件を選択しなければならない。The active oxygen suppressing substance in the grain raw material forms a complicated high molecular weight polymer together with other substances and is not active as it is. Therefore, the polymer bond is cut by means such as roasting, It is necessary to lower the molecular weight. However, if the roasting temperature is too high, the low molecular weight active oxygen suppressing substance will be inactivated, and thus the roasting conditions must be selected in consideration of this point as well.
【0018】このような条件を満足するためには、穀物
原料を100℃を超えない温度でゆっくり時間をかけて
焙煎しなければならない。具体的には、遠赤外線(特
に、波長4〜14μmの遠赤外線が好適である)を発生
する陶器などのセラミック製容器に穀物原料を入れ、温
度を90〜96℃程度に保った状態でゆっくりと攪拌し
ながら焙煎する。In order to satisfy such conditions, the grain raw material must be roasted slowly at a temperature not exceeding 100 ° C. for a long time. Specifically, the grain raw material is put into a ceramic container such as a pottery that emits far infrared rays (especially, far infrared rays having a wavelength of 4 to 14 μm is preferable), and the temperature is slowly maintained at about 90 to 96 ° C. And roast while stirring.
【0019】焙煎時間は、穀物種によっても異なるので
一概に規定できないが、30分〜3時間程度が好適であ
る。なお、焙煎方法は、穀物原料中の活性酸素抑制物質
が充分に低分子化し、かつその失活が防止できるもので
あれば、上記の方法に限定されるものではない。The roasting time varies depending on the grain type and cannot be specified unconditionally, but is preferably about 30 minutes to 3 hours. The roasting method is not limited to the above method as long as the active oxygen suppressing substance in the grain raw material has a sufficiently low molecular weight and its deactivation can be prevented.
【0020】次に、焙煎を施した上記穀物原料に麹(Asp
ergillus orizae)を加えて醗酵させる。醗酵条件は、2
0〜36℃で2〜6日間程度が好適である。醗酵器を使
って醗酵させる場合は、2〜3時間程度でよい。この醗
酵は、穀物原料中の活性酸素抑制物質の遊離低分子化を
一層促進するために行われるものであって、この工程を
経ることにより、単に焙煎しただけの穀物原料に比べて
活性酸素抑制物質の活性が著しく増強される。Next, koji (Asp
ergillus orizae) and ferment. Fermentation conditions are 2
About 2 to 6 days at 0 to 36 ° C is preferable. When fermenting using a fermentor, it takes about 2 to 3 hours. This fermentation is carried out in order to further promote the free and low molecular weight reduction of the active oxygen suppressing substance in the grain raw material, and by going through this process, the active oxygen content is higher than that of the simply roasted grain raw material. The activity of the inhibitor is significantly enhanced.
【0021】次に、醗酵を施した上記穀物原料を粉砕し
て微粉末とする。粉砕は、市販の粉砕機を使用して行え
ばよいが、粉砕機の種類によっては使用時に高熱が発生
し、活性酸素抑制物質を失活させてしまうものもある。
従って、石臼のように高熱が発生しないものを使用する
のが好ましい。Next, the fermented grain raw material is pulverized into a fine powder. The crushing may be performed using a commercially available crusher, but depending on the type of the crusher, high heat is generated during use, and the active oxygen suppressing substance is deactivated.
Therefore, it is preferable to use a stone mill that does not generate high heat.
【0022】次に、焙煎したゴマから採取した油(以
下、ゴマペースト油という)と生ゴマから採取した油と
を適当な割合で混合した油を用意し、この混合油に上記
微粉末を添加する。ゴマペースト油は、生ゴマを100
℃を超えない温度でゆっくり時間をかけて焙煎した後に
磨り潰し、これを圧搾して得られる油であるが、ゴマを
磨り潰してできた微細な固形物がそのまま残っているた
め、外観はペースト状を呈している。このゴマペースト
油には、低分子化された活性酸素抑制物質が豊富に含有
されており、これを用いることにより、活性酸素抑制物
質の活性が高い油性製剤を得ることができる。Next, an oil prepared by mixing an oil collected from roasted sesame (hereinafter referred to as sesame paste oil) and an oil collected from raw sesame at an appropriate ratio is prepared, and the above-mentioned fine powder is added to the mixed oil. Added. Sesame paste oil uses 100 sesame seeds
It is an oil obtained by roasting slowly at a temperature not exceeding ℃ and slowly crushing it, then squeezing it, but since the fine solid matter made by crushing sesame remains as it is, the appearance is It is pasty. This sesame paste oil contains abundant low molecular weight active oxygen suppressing substances, and by using this, an oily preparation having a high activity of active oxygen suppressing substances can be obtained.
【0023】但し、このゴマペースト油は粘度が高く、
かつ油滴のサイズも大きいため、このゴマペースト油に
前記微粉末を添加しただけのものは、疾患箇所である細
胞内への浸透力が乏しい。ところが、このゴマペースト
油に生ゴマから採取したゴマ油を加えると、油滴のサイ
ズが小さくなり、疾患箇所である細胞内への浸透力が向
上する。However, this sesame paste oil has a high viscosity,
Moreover, since the size of the oil droplets is also large, the sesame paste oil obtained by simply adding the fine powder described above has a poor penetrating power into cells, which is a disease site. However, when sesame oil collected from raw sesame is added to this sesame paste oil, the size of oil droplets is reduced, and the osmotic force into cells, which is a disease site, is improved.
【0024】生ゴマから採取した油とは、生ゴマをその
まま磨り潰し、これを圧搾した後に固形物を取り除いて
得られる油であり、市販されている通常のゴマ油はこれ
に相当する。ゴマペースト油と通常のゴマ油との混合比
は、添加される微粉末の量によっても異なるので一概に
規定できないが、ゴマペースト油1重量部に対して通常
のゴマ油1〜3重量部とするのが好適である。The oil collected from raw sesame is an oil obtained by crushing raw sesame as it is, squeezing the sesame and removing the solid matter, and commercially available ordinary sesame oil corresponds to this. The mixing ratio of sesame paste oil and normal sesame oil varies depending on the amount of fine powder to be added, and therefore cannot be specified unconditionally, but 1 to 3 parts by weight of normal sesame oil is used per 1 part by weight of sesame paste oil. Is preferred.
【0025】また、上記混合油とこれに添加される微粉
末との割合は、混合油が両者の合計量の60〜95重量
%となるようにする。混合油が60重量%未満のものは
細胞膜を通過する能力が低い。他方、混合油が95重量
%を超えるものは、有効成分である活性酸素抑制物質の
濃度が低いため、活性酸素や過酸化脂質の産生を抑制す
る効果も低下する。The ratio of the mixed oil to the fine powder added thereto is such that the mixed oil accounts for 60 to 95% by weight of the total amount of both. If the mixed oil is less than 60% by weight, the ability to pass through the cell membrane is low. On the other hand, when the mixed oil exceeds 95% by weight, the concentration of the active oxygen inhibitor which is an active ingredient is low, and therefore the effect of inhibiting the production of active oxygen and lipid peroxide also decreases.
【0026】上記混合油に微粉末を添加して得られた本
発明の油性製剤は、これを速やかにゼラチンカプセルな
どに封入して経口服用してもよいが、好ましくは20〜
35℃で3〜30日間程度、より好ましくは28〜30
℃で1週間程度熟成させるのがよい。The oily preparation of the present invention obtained by adding fine powder to the above mixed oil may be orally taken by rapidly encapsulating the oily preparation in a gelatin capsule or the like, but preferably 20 to
At 35 ° C. for about 3 to 30 days, more preferably 28 to 30
It is recommended to ripen at ℃ for about 1 week.
【0027】この熟成処理を施すことにより、微粉末中
に残っている麹による活性酸素抑制物質の遊離低分子化
が一層進むと共に、活性酸素抑制物質と混合油とがよく
馴染むため、有効成分の活性および細胞内への浸透力が
一層向上する。By performing this aging treatment, the active oxygen-suppressing substance is further reduced to a low molecular weight due to the koji remaining in the fine powder, and the active oxygen-suppressing substance and the mixed oil are well compatible with each other. The activity and penetration into cells are further improved.
【0028】本発明の油性製剤は、米胚芽または小麦胚
芽と大豆とからなる穀物原料(もしくはこれに糠、はと
むぎまたは小麦の少なくとも一つを加えた穀物原料)を
焙煎および醗酵させることなくそのまま微粉末化し、こ
れを前記の焙煎、醗酵処理を施した微粉末と共に前記混
合油に添加して調製することもできる。The oil-based preparation of the present invention is used as it is without roasting and fermenting a grain raw material comprising rice germ or wheat germ and soybean (or a grain raw material in which at least one of bran, hatomugi or wheat is added). It can also be prepared by adding it to the above mixed oil together with the above-mentioned roasted and fermented fine powder.
【0029】穀物原料を焙煎および醗酵させることなく
微粉末化したものは、有効成分である活性酸素抑制物質
が遊離低分子化していないが、これを焙煎、醗酵を施し
た微粉末と共に混合油に添加した場合は、後者の微粉末
中に残っている麹によって活性酸素抑制物質の遊離低分
子化が(カプセル封入後においても)徐々に進行するた
め、活性酸素や過酸化脂質の産生を抑制する効果が長期
間に渡って維持されるという利点がある。In the finely pulverized grain raw material without roasting and fermenting, the active oxygen-inhibiting substance which is the active ingredient does not have a free low molecular weight, but this is mixed with fine powder that has been roasted and fermented. When added to oil, the koji remaining in the latter fine powder gradually reduces the free molecular weight of the active oxygen suppressor (even after encapsulation), thus producing active oxygen and lipid peroxides. There is an advantage that the suppressing effect is maintained for a long period of time.
【0030】これに対し、焙煎、醗酵を施した微粉末の
みを使用した油性製剤は、カプセル封入後においても引
続き進行する酵素反応などによって、有効成分である活
性酸素抑制物質が徐々に分解するため、焙煎、醗酵を施
さない微粉末を加えたものに比べると有効期間が短い。On the other hand, in the oily preparation using only fine powder that has been roasted and fermented, the active oxygen-inhibiting substance as the active ingredient is gradually decomposed due to the enzymatic reaction which continues to proceed even after encapsulation. Therefore, the shelf life is shorter than that of the one added with fine powder that is not roasted or fermented.
【0031】しかし、焙煎および醗酵を施さない微粉末
の添加量が多すぎる場合は、有効成分の活性が低下して
しまうので、両者の割合は、焙煎、醗酵処理を施した微
粉末1重量部に対してこれらの処理を施さない微粉末0.
5〜1重量部程度とするのが良い。なお、この場合も、
混合油と上記二種の微粉末との割合は、混合油が全量の
60〜95重量%となるようにする。However, if the addition amount of the fine powder that is not roasted or fermented is too large, the activity of the active ingredient will be reduced, so the ratio of both is 1 fine powder that has been roasted and fermented. Fine powder without these treatments for parts by weight.
It is preferable that the amount is about 5 to 1 part by weight. In this case, too,
The ratio of the mixed oil to the above-mentioned two kinds of fine powders is such that the mixed oil is 60 to 95% by weight of the total amount.
【0032】以上のようにして得られる本発明の油性製
剤は、活性酸素抑制物質の活性および細胞内への浸透力
がいずれも高く、後述する臨床試験の結果からも明らか
なように、既存の抗炎症剤などでは治療効果が不充分で
あった各種炎症、難病に対して著効を発揮する。The oily preparation of the present invention obtained as described above has a high activity of the active oxygen inhibitor and a high penetrating power into cells, and as is clear from the results of the clinical tests described below, the existing It exerts a remarkable effect against various inflammations and intractable diseases for which the therapeutic effect was insufficient with anti-inflammatory agents.
【0033】本発明の油性製剤は、ゼラチンカプセルな
どに封入し、医薬品として経口服用する。また、皮膚
炎、しみ、そばかすなどの色素異常沈着やシワ(皺)な
どの場合には、直接患部に塗布してもよい。適応症とし
ては、上記皮膚炎などの他、慢性関節リウマチ、血栓性
静脈炎、進行性全身性皮膚硬化症、バージャー氏病、レ
イノー氏病、難治性皮膚潰瘍などの成人病、難病が挙げ
られるが、その他各種公害病、火傷、外傷、疲労、宿
酔、便秘などの治療、予防にも効果がある。The oily preparation of the present invention is enclosed in a gelatin capsule or the like and orally taken as a medicine. In addition, in the case of pigmentation abnormalities such as dermatitis, spots, and freckles, and wrinkles, it may be directly applied to the affected area. Indications include, in addition to the above dermatitis, chronic diseases such as rheumatoid arthritis, thrombophlebitis, progressive systemic skin sclerosis, Burger's disease, Raynaud's disease, and intractable diseases such as intractable skin ulcers. However, it is also effective in treating and preventing various pollution diseases, burns, injuries, fatigue, sickness, constipation, etc.
【0034】また、本発明の油性製剤は、穀物、麹およ
びゴマのみを原料にしていることから副作用が全くない
ので、健康食品として経口服用し、健康の維持増進に役
立てることもできる。なお、製剤化に際しては、必要に
応じて各種ビタミン、ミネラルなどの補助的な医薬ない
しは保健上有用な成分や、香料、矯味料、着色剤などを
添加してよいことはいうまでもない。The oil-based preparation of the present invention has no side effects because it is made of only cereals, koji and sesame, so that it can be taken orally as a health food to help maintain and improve health. Needless to say, when formulating, auxiliary drugs such as various vitamins and minerals or components useful for health, flavors, flavors, coloring agents and the like may be added, if necessary.
【0035】[0035]
【実施例】米胚芽、大豆、糠、ハトムギ、小麦各1重量
部を4〜14μmの遠赤外線を放射する陶器製の鍋に仕
込み、90〜96℃で3時間、ゆっくり攪拌しながら焙
煎した。次にタネ麹を全量の3%加え、36〜40℃で
72時間醗酵させた後、石臼を使って微粉末とした。ま
た、焙煎も醗酵もしない上記5種の穀物原料を石臼で挽
き、同量の微粉末を得た。一方、ゴマを上記の同様の方
法で焙煎し、これを石臼で磨り潰した後、圧搾してゴマ
ペースト油を得た。[Examples] Rice germ, soybean, bran, adlay, and wheat (1 part by weight each) were placed in a pot made of earthenware that emits far infrared rays of 4 to 14 μm, and roasted at 90 to 96 ° C. for 3 hours with slow stirring. . Next, 3% of the total amount of seed koji was added and fermented at 36 to 40 ° C. for 72 hours, and then finely powdered using a stone mill. Further, the above-mentioned five kinds of grain raw materials which were neither roasted nor fermented were ground with a stone mill to obtain the same amount of fine powder. On the other hand, sesame was roasted by the same method as described above, ground with a stone mill, and then pressed to obtain sesame paste oil.
【0036】次に、ゴマペースト油28.1重量部と市販
のゴマ油48.9重量部とを混ぜ、これに焙煎および醗酵
処理した前記微粉末11.5重量部および焙煎も醗酵もし
ない前記微粉末11.5重量部をそれぞれ添加し、均一に
攪拌した。これを28℃で1週間熟成させた後、ゼラチ
ンカプセルに封入して油性製剤を得た。Next, 28.1 parts by weight of sesame paste oil and 48.9 parts by weight of commercially available sesame oil were mixed, and 11.5 parts by weight of the fine powder roasted and fermented and neither roasted nor fermented 11.5 parts by weight of the fine powder was added to each and stirred uniformly. This was aged at 28 ° C. for 1 week and then encapsulated in a gelatin capsule to obtain an oily preparation.
【0037】[0037]
〔I〕試験管テスト 油性の部位に到達、浸透する能力の試験管での測定方
法として、油性の不飽和脂肪酸(docosahexaenoic acid)
が紫外線の発生する活性酵素と反応して過酸化脂質を生
成する反応(TBA(thiobarbituric acid) 反応)系に
本発明油性製剤(実施例)を添加し、この過酸化脂質の
生成が抑制される程度を測定した。[I] Test tube test An oily unsaturated fatty acid (docosahexaenoic acid) is used as a method for measuring the ability of a test tube to reach and penetrate oily sites.
When the oily preparation of the present invention (Example) is added to a reaction system (TBA (thiobarbituric acid) reaction) in which is reacted with an active enzyme generated by ultraviolet rays to produce lipid peroxide, the production of this lipid peroxide is suppressed. The degree was measured.
【0038】すなわち、docosahexaenoic acid原液を1
00倍に希釈したもの0.1ccを用い、本発明油性製剤の
検体1.8mg/ml を添加し、産生される過酸化脂質をTB
A反応で測定した。TBA反応は、7% sodium dodecy
l sulfate 0.2ml、0.1N HCl2ml、phosphotungstic aci
d 0.3mlを混合し、そこに1.8mg/ml の検体を加え、0.6
7%TBAと酢酸とを1:1に混合した試薬1mlを添加
し、蛍光分光光度計を用いて excitation 515nm, emiss
ion 553nm で測定を行った。That is, 1 stock solution of docosahexaenoic acid
Using 0.1 cc diluted to 00 times, 1.8 mg / ml of the sample of the oily preparation of the present invention was added to produce the lipid peroxide produced in TB.
It was measured by A reaction. TBA reaction is 7% sodium dodecy
l sulfate 0.2ml, 0.1N HCl2ml, phosphotungstic aci
d 0.3 ml was mixed, and 1.8 mg / ml sample was added thereto, and 0.6
Add 1 ml of a 1: 1 mixture of 7% TBA and acetic acid and use a fluorescence spectrophotometer to excite at 515 nm, emiss.
The measurement was performed at ion 553 nm.
【0039】比較例として、特許第1366268号の
植物系栄養剤(比較例1)および特開昭63−7983
4号公報記載の活性酸素抑制組成物(比較例2)を検体
として用い、同様の測定を行った。結果を表1に示す。As comparative examples, the plant nutritional supplement of Japanese Patent No. 1366268 (Comparative Example 1) and JP-A-63-7983.
The same measurement was carried out using the active oxygen suppressing composition (Comparative Example 2) described in JP-A No. 4 as a sample. The results are shown in Table 1.
【0040】[0040]
【表1】 [Table 1]
【0041】−テスト結果− いずれの検体も油性の不飽和脂肪酸(docosahexaenoic a
cid)が紫外線(1O2)に照射されて過酸化脂質(TBA r
eactive substances)が生成されるのを有意に抑制した
が、特に本発明油性製剤は、これを著名に抑制(P<0.
0001) した。この結果は、本発明油性製剤が従来の類似
品(比較例1、比較例2)に比べて活性酸素抑制物質の
活性が高く、しかも疾患が生じている細胞内への浸透力
が高いことを裏付けている。-Test Results- All samples were oily unsaturated fatty acids (docosahexaenoic a
(Cid) is irradiated with ultraviolet rays ( 1 O 2 ) and lipid peroxide (TBA r
The production of eactive substances was significantly suppressed, but the oily preparation of the present invention markedly suppressed this (P <0.
0001) I did. This result indicates that the oil-based preparation of the present invention has a higher activity of the active oxygen suppressor than the conventional similar products (Comparative Example 1 and Comparative Example 2) and has a high penetrating power into diseased cells. I support it.
【0042】本発明油性製剤中に含まれる低分子活性
酸素抑制物質に同位元素(3H)を標識した〔3,4-3H
2 〕−活性酸素抑制物質を作り、これを試験管中のヒト
組織球中に添加し、その細胞膜に結合した〔 3H2 〕の
カウント(cpm) をシンチレーションカウンターで測定す
ることにより、細胞膜へ到達する能力をテストした(標
識したtritiated thymidine は 2Ci/mM)。The isotope (3 H) labeled to a low molecular weight active oxygen inhibitors which are included in the present invention the oily formulation [3,4-3 H
2 ] -The active oxygen inhibitor was prepared, added to human histiocytes in a test tube, and the count (cpm) of [ 3 H 2 ] bound to the cell membrane was measured by a scintillation counter to obtain a cell membrane. The ability to reach was tested (2 Ci / mM labeled tritiated thymidine).
【0043】比較例1および比較例2についても、同様
のテストを行った。結果を表2に示す。表2から明らか
なように、本発明油性製剤は、比較例1や比較例2に比
べて細胞膜への親和性が最も高かった。Similar tests were conducted on Comparative Examples 1 and 2. The results are shown in Table 2. As is clear from Table 2, the oily preparation of the present invention had the highest affinity for the cell membrane as compared with Comparative Examples 1 and 2.
【0044】[0044]
【表2】 [Table 2]
【0045】本発明油性製剤を超音波にかけてその生
体換算濃度が1.6mg/ml となるように活性酸素測定溶液
である活性酸素発生システム(好中球とキサンチン−キ
サンチン酸化酵素)に添加して3種の活性酸素
(O2 - 、H2 O2 、OH・)を測定し、未添加の場合
(対照)の活性酸素値と比較した。なお、生体換算濃度
とは1日常用内服量(本発明油性製剤の場合は9g)が
生体に吸収された場合、血液中に本発明油性製剤が存在
すると仮定される量である。The oily preparation of the present invention is subjected to ultrasonic waves and added to an active oxygen generating system (neutrophil and xanthine-xanthine oxidase) which is an active oxygen measuring solution so that the bio-converted concentration thereof becomes 1.6 mg / ml. Three types of active oxygen (O 2 − , H 2 O 2 , OH.) Were measured and compared with the active oxygen value in the case of no addition (control). The bio-concentration is the amount assumed to exist in the blood when one daily oral dose (9 g in the case of the oil-based preparation of the present invention) is absorbed by the living body.
【0046】3種の活性酸素の測定方法は、次のとおり
である。O2 - は、O2 - がフェリチトクロームCを還
元する量を Beckmanの spectrophotometerの波長 550nm
で測定し、O2 - に換算する方法を用い、H2 O2 は、
peroxidase存在下で scopoletin の発する蛍光を減少さ
せることから、 scopoletin と peroxidase とを用い、
scopoletin の蛍光減少度を日立製の蛍光分光光度計で
excitation 370nm、emission 460nmで測定した。OH・
は、α-keto-methiol-butylic acid(KMB) とOH・とが
反応してエチレンガスを生成する原理を利用し、エチレ
ンガスを日立製のガスクロマトグラフィーにより定量
し、OH・に換算する方法を用いた。比較例1および比
較例2についても、同様のテストを行った。結果を表3
に示す。The three types of active oxygen measuring methods are as follows. O 2 − is the amount of O 2 − that reduces ferricytochrome C determined by Beckman's spectrophotometer at a wavelength of 550 nm.
H 2 O 2 is converted into O 2 − using the method
Since the fluorescence emitted by scopoletin is reduced in the presence of peroxidase, scopoletin and peroxidase were used.
Fluorescence reduction of scopoletin with Hitachi spectrophotometer
It was measured at excitation 370 nm and emission 460 nm. OH
Is a method of quantifying ethylene gas by gas chromatography made by Hitachi and converting it into OH. By utilizing the principle that α-keto-methiol-butylic acid (KMB) reacts with OH. To produce ethylene gas. Was used. Similar tests were performed for Comparative Example 1 and Comparative Example 2. The results are shown in Table 3.
Shown in.
【0047】[0047]
【表3】 [Table 3]
【0048】−テスト結果− 本発明油性製剤の活性酸素抑制効果は、比較例2に比べ
て若干劣るが、同じ油性の比較例1と比べて強力な活性
酸素抑制効果を発揮した。しかし、比較例2は、前記表
1および表2から明らかなように、油性物質の含有量が
少ないため、疾患が生じている細胞に到達する能力が低
い。-Test Results- Although the active oxygen suppressing effect of the oil-based preparation of the present invention is slightly inferior to that of Comparative Example 2, a stronger active oxygen suppressing effect was exhibited as compared with Comparative Example 1 having the same oiliness. However, as is clear from Tables 1 and 2 above, Comparative Example 2 has a low ability to reach cells in which a disease has occurred because the content of the oily substance is small.
【0049】従って、総合的に判断すると、活性酸素抑
制効果が高く、しかも疾患箇所である細胞内への浸透力
が高い本発明油性製剤は、活性酸素抑制製剤として最も
優れたものである。Therefore, when comprehensively judged, the oily preparation of the present invention has a high effect of suppressing active oxygen and has a high penetrating power into the cells at the disease site, and is the most excellent active oxygen suppressing preparation.
【0050】〔II〕臨床テスト 今まで、非ステロイド系消炎剤、ステロイドおよび比較
例2(活性酸素抑制組成物)のいずれに対しても抵抗あ
るいは憎悪していた主として自己免疫疾患、慢性関節リ
ウマチを始めとする膠原病、血液循環障害、腎炎、肝硬
変、しみ・そばかすなどの患者96例を対象として治療
効果を調べた。結果を表4に示す。[II] Clinical test Up to now, mainly autoimmune diseases and rheumatoid arthritis, which have been resistant to or exacerbated by any of non-steroidal anti-inflammatory agents, steroids and Comparative Example 2 (active oxygen suppressing composition), have been investigated. The therapeutic effect was examined in 96 patients with collagen disease, blood circulation disorder, nephritis, cirrhosis, and spots / freckles. The results are shown in Table 4.
【0051】[0051]
【表4】 [Table 4]
フロントページの続き (51)Int.Cl.5 識別記号 庁内整理番号 FI 技術表示箇所 A61K 9/107 W 7329−4C Continuation of the front page (51) Int.Cl. 5 Identification number Office reference number FI technical display location A61K 9/107 W 7329-4C
Claims (7)
穀物原料を100℃を超えない温度で焙煎し、次いで麹
を加えて醗酵させた後に微粉末化したものを、前記の方
法で焙煎したゴマから採取した油と生ゴマから採取した
油とからなる混合油に添加してなり、前記微粉末と前記
混合油の合計量に対する前記混合油の割合を60〜95
重量%にしたことを特徴とする油性製剤。1. A grain raw material comprising rice germ or wheat germ and soybean is roasted at a temperature not exceeding 100 ° C., then malted by adding koji and then pulverized, and then roasted by the above method. It is added to a mixed oil consisting of oil collected from roasted sesame and oil collected from raw sesame, and the ratio of the mixed oil to the total amount of the fine powder and the mixed oil is 60 to 95.
An oil-based preparation characterized by being made into a weight%.
穀物原料を焙煎および醗酵させることなく微粉末化し、
これを請求項1記載の微粉末と共に混合油に添加してな
ることを特徴とする請求項1記載の油性製剤。2. A grain raw material composed of rice germ or wheat germ and soybean is pulverized into fine powder without roasting and fermentation,
The oily preparation according to claim 1, which is obtained by adding this to the mixed oil together with the fine powder according to claim 1.
糠、はとむぎまたは小麦の少なくとも一つを含んだ穀物
原料を用いることを特徴とする請求項1または2記載の
油性製剤。3. In addition to rice germ or wheat germ and soybean,
The oil-based preparation according to claim 1 or 2, wherein a grain raw material containing at least one of bran, hatomugi or wheat is used.
品として経口投与することを特徴とする請求項1または
2記載の油性製剤。4. The oily preparation according to claim 1, which is encapsulated and orally administered as a medicine or health food.
焙煎する際、波長4〜14μmの遠赤外線を用いること
を特徴とする油性製剤の製造方法。5. A method for producing an oily preparation, which comprises using far infrared rays having a wavelength of 4 to 14 μm when roasting the grain raw material according to claim 1, 2 or 3.
焙煎した後、20〜36℃で2〜6日間醗酵させること
を特徴とする油性製剤の製造方法。6. A method for producing an oily preparation, which comprises roasting the grain raw material according to claim 1, 2 or 3 and then fermenting the grain raw material at 20 to 36 ° C. for 2 to 6 days.
合油に添加し、20〜35℃で3〜30日間熟成させる
ことを特徴とする油性製剤の製造方法。7. A method for producing an oily preparation, which comprises adding the fine powder according to claim 1, 2 or 3 to a mixed oil and aging it at 20 to 35 ° C. for 3 to 30 days.
Priority Applications (20)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4162666A JP2955126B2 (en) | 1992-06-22 | 1992-06-22 | Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof |
| GB9312763A GB2268185B (en) | 1992-06-22 | 1993-06-21 | Oily preparation and method of production thereof |
| NO932282A NO306932B1 (en) | 1992-06-22 | 1993-06-21 | Oily preparation and method of preparation thereof |
| IT93TO000448A IT1266950B1 (en) | 1992-06-22 | 1993-06-21 | OILY PREPARATION CONTAINING ANTIOXIDANT SUBSTANCES FOR HUMAN USE AND PROCEDURE FOR ITS PRODUCTION |
| SE9302141A SE512781C2 (en) | 1992-06-22 | 1993-06-21 | Oil preparations with high activity antioxidants, and process for their preparation |
| CA002098893A CA2098893C (en) | 1992-06-22 | 1993-06-21 | Antioxidant composition of natural products and method of production thereof |
| CH186493A CH686482A5 (en) | 1992-06-22 | 1993-06-21 | oily preparation and process for obtaining it |
| DE4320526A DE4320526C2 (en) | 1992-06-22 | 1993-06-21 | Oil preparation and method of making the same |
| DK073293A DK169714B1 (en) | 1992-06-22 | 1993-06-21 | Oily Preparation and Method of Preparation |
| AT0122893A AT406935B (en) | 1992-06-22 | 1993-06-22 | METHOD FOR PRODUCING AN OILY PREPARATION |
| KR1019930011403A KR0138738B1 (en) | 1992-06-22 | 1993-06-22 | Oily preparation and method thereof |
| FR9307557A FR2692442B1 (en) | 1992-06-22 | 1993-06-22 | OILY PREPARATION AND PROCESS FOR PREPARING THE SAME. |
| AU41432/93A AU656681B2 (en) | 1992-06-22 | 1993-06-22 | Oily preparation and method of production thereof |
| BE9300641A BE1006911A3 (en) | 1992-06-22 | 1993-06-22 | Oily composition and method of preparation. |
| TW082104986A TW269630B (en) | 1992-06-22 | 1993-06-22 | |
| CN93109052A CN1065433C (en) | 1992-06-22 | 1993-06-22 | Oily preparation and method of production thereof |
| NL9301083A NL193398C (en) | 1992-06-22 | 1993-06-22 | Antioxidant oil composition and method for its preparation. |
| IS4038A IS1657B (en) | 1992-06-22 | 1993-06-22 | Process for producing oily mixture |
| ES09301404A ES2049189B1 (en) | 1992-06-22 | 1993-06-22 | METHOD FOR THE PRODUCTION OF AN OILY PREPARATION. |
| HK98106356A HK1007165A1 (en) | 1992-06-22 | 1998-06-24 | Oily preparation and method of production thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP4162666A JP2955126B2 (en) | 1992-06-22 | 1992-06-22 | Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH069421A true JPH069421A (en) | 1994-01-18 |
| JP2955126B2 JP2955126B2 (en) | 1999-10-04 |
Family
ID=15758977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP4162666A Expired - Lifetime JP2955126B2 (en) | 1992-06-22 | 1992-06-22 | Pharmaceutical oleaginous preparation, food oleaginous preparation and production method thereof |
Country Status (20)
| Country | Link |
|---|---|
| JP (1) | JP2955126B2 (en) |
| KR (1) | KR0138738B1 (en) |
| CN (1) | CN1065433C (en) |
| AT (1) | AT406935B (en) |
| AU (1) | AU656681B2 (en) |
| BE (1) | BE1006911A3 (en) |
| CA (1) | CA2098893C (en) |
| CH (1) | CH686482A5 (en) |
| DE (1) | DE4320526C2 (en) |
| DK (1) | DK169714B1 (en) |
| ES (1) | ES2049189B1 (en) |
| FR (1) | FR2692442B1 (en) |
| GB (1) | GB2268185B (en) |
| HK (1) | HK1007165A1 (en) |
| IS (1) | IS1657B (en) |
| IT (1) | IT1266950B1 (en) |
| NL (1) | NL193398C (en) |
| NO (1) | NO306932B1 (en) |
| SE (1) | SE512781C2 (en) |
| TW (1) | TW269630B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Oral whitening agent and whitening food |
| JP2000159682A (en) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | Crude drug antitumor activity enhancing method, antitumor activity enhancing crude drug-containing composition, antitumor efficacy evaluating method of crude drug treatment, and antitumor efficacy evaluating method of crude drug |
| JP2021031439A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | A method for producing an active oxygen scavenger for oral ingestion that suppresses the runaway of immune cells and protects against damage to DNA and telomeres. |
| JP2021031440A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | Antitumor agent set having active oxygen removing agent containing low molecular antioxidizing compound derived from natural product and immunity activator derived from natural product which is used for enhancing macrophages and lymphocytes |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2946548A (en) * | 1956-09-10 | 1960-07-26 | Lars G V Largelins | Supporting clamp |
| GB9509811D0 (en) * | 1995-05-15 | 1995-07-05 | Cerestar Holding Bv | Co-pressing of oilseeds |
| DE19715878A1 (en) * | 1997-04-16 | 1998-10-22 | Pharmaberatung Fuer Ernaehrung | Products to aid the treatment of atopic dermatitis |
| AUPP574298A0 (en) * | 1998-09-07 | 1998-10-01 | Jacobs, David Ian | Pharmaceutical preparation |
| JP2000239187A (en) * | 1999-02-22 | 2000-09-05 | Dotto:Kk | Composition for nasal absorption |
| JP2001199892A (en) * | 2000-01-17 | 2001-07-24 | Kozo Niwa | Method for enhancing anti-tumor activity of amygdalin-containing substance, composition containing anti-tumor activity-enhancing amygdalin-containing substance, method for evaluating anti-tumor efficacy of treatment with amygdalin-containing substance, and method for evaluating anti-tumor efficacy of amygdalin-containing substance |
| JP4621444B2 (en) * | 2004-06-18 | 2011-01-26 | 株式会社ヴァリダックス | Method for producing antitumor substance |
| DE102007011985B4 (en) | 2007-03-09 | 2022-10-20 | Markus Greim | Mortar measuring cell for rotation viscometer |
| FR2956324A1 (en) * | 2010-01-18 | 2011-08-19 | Valerie Baille | Plant complex, useful to e.g. prepare a composition in pharmaceutical, cosmetic or nutrition, comprises a bamboo polyphenolic extract, a cell preparation of Ginkgo biloba and a rice bran oil preparation |
| CN104178334A (en) * | 2013-05-24 | 2014-12-03 | 北京中天金谷粮油工程技术有限公司 | Process for infrared baking of sesame to produce oil |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6020389B2 (en) * | 1983-06-07 | 1985-05-21 | 工業技術院長 | Separation method of tocopherols |
| JPS60110269A (en) * | 1983-11-18 | 1985-06-15 | Kimimoto Wada | Preparation of vegetable nutrient |
| JPS6236327A (en) * | 1985-08-08 | 1987-02-17 | Kozo Niwa | Chinese herbal remedy |
| JPS6379834A (en) * | 1986-09-25 | 1988-04-09 | Kozo Niwa | Active oxygen suppressive composition |
| JPH023495A (en) * | 1988-06-13 | 1990-01-09 | Okuno Seiyaku Kogyo Kk | Antioxidant |
| JPH0441436A (en) * | 1990-06-04 | 1992-02-12 | Sodetsukusu Kk | Antioxidant composition |
| JPH07119176B2 (en) * | 1990-09-28 | 1995-12-20 | アサヒビール株式会社 | Anti-active oxygen acting composition and anti-active oxygen agent containing the same as an active ingredient, food, cosmetics and pharmaceuticals |
| JP3357383B2 (en) * | 1991-08-14 | 2002-12-16 | 昌宏 黒田 | Low molecular weight plant composition |
| JP2647774B2 (en) * | 1991-11-28 | 1997-08-27 | 株式会社 エイオーエイ・ジャパン | Plant antioxidant composition |
-
1992
- 1992-06-22 JP JP4162666A patent/JP2955126B2/en not_active Expired - Lifetime
-
1993
- 1993-06-21 DE DE4320526A patent/DE4320526C2/en not_active Expired - Lifetime
- 1993-06-21 CH CH186493A patent/CH686482A5/en not_active IP Right Cessation
- 1993-06-21 SE SE9302141A patent/SE512781C2/en unknown
- 1993-06-21 DK DK073293A patent/DK169714B1/en not_active IP Right Cessation
- 1993-06-21 NO NO932282A patent/NO306932B1/en not_active IP Right Cessation
- 1993-06-21 CA CA002098893A patent/CA2098893C/en not_active Expired - Lifetime
- 1993-06-21 GB GB9312763A patent/GB2268185B/en not_active Expired - Lifetime
- 1993-06-21 IT IT93TO000448A patent/IT1266950B1/en active IP Right Grant
- 1993-06-22 CN CN93109052A patent/CN1065433C/en not_active Expired - Lifetime
- 1993-06-22 NL NL9301083A patent/NL193398C/en not_active IP Right Cessation
- 1993-06-22 ES ES09301404A patent/ES2049189B1/en not_active Expired - Fee Related
- 1993-06-22 AT AT0122893A patent/AT406935B/en not_active IP Right Cessation
- 1993-06-22 TW TW082104986A patent/TW269630B/zh not_active IP Right Cessation
- 1993-06-22 KR KR1019930011403A patent/KR0138738B1/en not_active Expired - Lifetime
- 1993-06-22 FR FR9307557A patent/FR2692442B1/en not_active Expired - Lifetime
- 1993-06-22 IS IS4038A patent/IS1657B/en unknown
- 1993-06-22 BE BE9300641A patent/BE1006911A3/en not_active IP Right Cessation
- 1993-06-22 AU AU41432/93A patent/AU656681B2/en not_active Expired
-
1998
- 1998-06-24 HK HK98106356A patent/HK1007165A1/en not_active IP Right Cessation
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH11269066A (en) * | 1998-03-20 | 1999-10-05 | Kao Corp | Oral whitening agent and whitening food |
| JP2000159682A (en) * | 1998-09-17 | 2000-06-13 | Kozo Niwa | Crude drug antitumor activity enhancing method, antitumor activity enhancing crude drug-containing composition, antitumor efficacy evaluating method of crude drug treatment, and antitumor efficacy evaluating method of crude drug |
| JP2021031439A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | A method for producing an active oxygen scavenger for oral ingestion that suppresses the runaway of immune cells and protects against damage to DNA and telomeres. |
| JP2021031440A (en) * | 2019-08-26 | 2021-03-01 | 雄二 松川 | Antitumor agent set having active oxygen removing agent containing low molecular antioxidizing compound derived from natural product and immunity activator derived from natural product which is used for enhancing macrophages and lymphocytes |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NL192914C (en) | Method for the preparation of an antioxidant preparation and preparation obtained therewith. | |
| CA2631850C (en) | Equol-containing fermentation product of soybean embryonic axis, and method for production thereof | |
| JPH069421A (en) | Oily preparation and method for producing the same | |
| CN113855609A (en) | Glutinous rice fermented extract and anti-eczema application thereof | |
| JP3933511B2 (en) | Skin cosmetics and beauty food and drink | |
| JP3977889B2 (en) | Drugs containing buckwheat husk extract as an active ingredient | |
| NL1017117C2 (en) | Method for enhancing the anti-tumor activity of an amygdalin-containing material, preparation containing enhanced amygdalin-containing material, method for assessing the anti-tumor effectiveness of a treatment of amygdalin-containing material, and method for evaluating amygdalin-containing anti-tumor material. | |
| JP2010280621A (en) | Antioxidants, anti-inflammatory agents, anti-aging agents, skin cosmetics, and foods and drinks | |
| JP4672269B2 (en) | Anti-aging agent, platelet aggregation inhibitor, antioxidant, antiallergic agent, skin cosmetics and food and drink | |
| JP3386155B2 (en) | Cosmetic cream, cream for preventing or treating freckles, freckles, cream for preventing or treating wrinkles, and cream for preventing or treating sunburn | |
| KR102256823B1 (en) | Complex composition comprising DHA derivatives for anti-wrinkle, improving atopic dermatitis and enhancing skin barrier | |
| WO2000069453A1 (en) | Sod-like composition and blood-pressure controlling agent | |
| JP3282032B2 (en) | Active oxygen suppression composition | |
| RU2195306C1 (en) | Biologically active substances extraction method | |
| JP3900967B2 (en) | Antioxidants, skin cosmetics and beauty foods and drinks | |
| JP2001288116A (en) | Active oxygen resistant composition and method of producing the same | |
| EP1161253A1 (en) | Use of hop flowers for medicinal treatments | |
| JP3308497B2 (en) | SOD-like extract composition extracted from coffee beans | |
| KR20250082309A (en) | Anti-aging composition containing rice fermentation active ingredient | |
| JP4499382B2 (en) | Lipolysis accelerator | |
| KR20130117158A (en) | Composition for antioxidant comprising extract of lagerstroemia ovalifolia | |
| HK1259202A1 (en) | A method for producing an equol- and ornithine-containing fermented soybean hypocotyl material | |
| HK1259202B (en) | A method for producing an equol- and ornithine-containing fermented soybean hypocotyl material |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20080716 Year of fee payment: 9 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090716 Year of fee payment: 10 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100716 Year of fee payment: 11 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110716 Year of fee payment: 12 |
|
| FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20120716 Year of fee payment: 13 |
|
| EXPY | Cancellation because of completion of term |